Can Vir/GSK’s COVID-19 Antibody Prove Its Worth In Early Disease?
VIR-7831 Suffers Setback In NIH Study
Other antibody treatments have shown efficacy in early-stage disease after faltering in hospitalized patients.
You may also be interested in...
GSK could soon see an approval in Japan for its antibody therapy following a filing for emergency use, while South Korea looks to build its mRNA vaccine capabilities through a new consortium.
Also, Moderna completed the submission of the BLA for mRNA-1273’s FDA approval, Pfizer starts a rolling submission for a booster shot and Brii Biosciences announced data for its two-antibody antiviral cocktail, and Japan withdraws selected lots of Moderna's vaccine over contamination worries.
Top-line Phase II data show that a combo of bamlanivimab and VIR-7831, neutralizing antibodies to the SARS-CoV-2 spike protein, yielded a relative 70% reduction in viral load.